Sanofi (NASDAQ:SNY) Shares Bought by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky boosted its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 7.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 409,290 shares of the company's stock after acquiring an additional 27,330 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Sanofi were worth $19,740,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State Street Corp increased its position in shares of Sanofi by 0.5% in the 3rd quarter. State Street Corp now owns 56,734 shares of the company's stock valued at $3,270,000 after acquiring an additional 264 shares during the period. Barclays PLC increased its holdings in shares of Sanofi by 107.5% in the third quarter. Barclays PLC now owns 639,772 shares of the company's stock valued at $36,869,000 after purchasing an additional 331,445 shares during the period. Geode Capital Management LLC raised its stake in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after purchasing an additional 16,780 shares during the last quarter. World Investment Advisors LLC lifted its holdings in shares of Sanofi by 1,020.5% during the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock worth $2,791,000 after purchasing an additional 44,108 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Sanofi in the third quarter valued at approximately $219,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

SNY traded down $1.22 on Friday, reaching $52.32. The stock had a trading volume of 5,488,688 shares, compared to its average volume of 2,388,797. The business's 50-day moving average price is $54.56 and its two-hundred day moving average price is $52.11. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12. The company has a market cap of $132.17 billion, a P/E ratio of 21.01, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. Sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be paid a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

Analyst Ratings Changes

A number of equities analysts have issued reports on SNY shares. BNP Paribas initiated coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. The Goldman Sachs Group initiated coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Sanofi has a consensus rating of "Moderate Buy" and a consensus price target of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.